PRAME expression is associated with poorer response to nilotinib in late CP patients
| . | PRAME detected, no. (%) . | PRAME not detected, no. (%) . |
|---|---|---|
| Responded to nilotinib | 5 (38) | 8 (62) |
| Failed nilotinib | 10 (83) | 2 (17) |
| . | PRAME detected, no. (%) . | PRAME not detected, no. (%) . |
|---|---|---|
| Responded to nilotinib | 5 (38) | 8 (62) |
| Failed nilotinib | 10 (83) | 2 (17) |
Twenty-five late CP patients received nilotinib as second-line therapy after imatinib failure. PRAME expression was measured prior to beginning nilotinib therapy using QPCR. PRAME expression was detected in 10 (83%) of 12 patients who failed nilotinib therapy compared with 5 (38%) of 13 patients who responded (P = .04).